| |
Space travelers experience many physiological
changes as they orbit Earth. An astronaut's body, once free of
a 1-gravity pull, experiences a redistribution of body fluids.
Proportionately more blood surges through the head, neck, and
chest. Blood plasma volume is affected, and the number of red
blood cells eventually decreases, leading to a form of space
anemia. These effects and others are under study by NASA physicians
to better appreciate how the human body reacts and adapts to
microgravity and then readjusts to the Earth's gravity, once
returned from space.
As part of these studies, NASA sought development of a device
for the collection and real-time analysis of blood and other
bodily fluids on missions without centrifugation. A method to
collect and store such samples was invented by NASA and has been
licensed to DBCD, Inc., of Webster, Texas. DBCD was formed in
1997 to commercialize the technology.
Under a patent licensing agreement from NASA, DBCD is now
manufacturing a completely new range of blood separation products.
These products incorporate the patented separation technology
developed by NASA engineers. In May 1998, DBCD released its first
product, the ProSeptorTM, a blood drop device, and
sales have begun. The ProSeptorTM 200, capable of
collecting 150 microliters of serum, was also released.
The patented method and technology separate a relatively large
volume of blood into cellular and acellular fractions without
the need of a spinning centrifuge to accomplish this division.
DBCD's ProSeptorTM products can provide serum or plasma
from whole blood volumes of 20 microliters to 4 milliliters.
These devices have a fibrous filter with a pore size of less
than about 3 microns and are coated with a mixture of mannitol
and plasma fraction protein. This coating causes the cellular
fraction to be trapped by the small pores, leaving the cellular
fraction intact on the fibrous filter. Meanwhile, the acellular
fraction passes unaltered through the filter for collection from
the serum sample collection chamber.
DBCD devices permit the collection of serum, anywhere, anytime,
and from any species. No longer are heavy centrifuges required
to be transported to remote sites, nor do police detectives have
to hurry back to a lab to avoid sample spoilage. Expensive overnight
parcels can be replaced by using the DBCD equipment.
Now manufacturing a range of blood separation products, DBCD
services include customizing a blood separation system for a
customer's instrumentation. DBCD's processing separator system
equipment allows a user to collect, in only seconds to minutes,
quantities of serum/plasma from whole blood that are of excellent
quality.
ProSeptorTM 200 is designed to collect around 150
microliters of serum from 0.5 milliliters of blood in a laboratory
or remote setting. The serum, which is collected on an easily
removed collector, can be squeezed off for immediate analysis,
frozen, or dried for later study. An Express Pouch is a specifically
designed plastic pouch with storage material incorporated. The
ProSeptorTM device or collection layer of the ProSeptorTM
200 can be placed in this pouch to dry and then be mailed to
the laboratory for later analysis.
"DBCD has had great response from the community, diagnostic
companies, and distributors regarding our products," says
Eden Fields, president of DBCD. "NASA provides a great environment
for development of products that can be beneficial to society.
This technology is a good example of such a project," Fields
adds.
ProSeptorTM is a trademark of DBCD,
Inc.


| DBCD, Inc.,
has developed portable blood collection products that separate
blood without the need of a spinning centrifuge. |
|
|